Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CPT1A | P50416 | 13/20 | 0.41 |
| ▸ | CPT2 | P23786 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.39 |
| ▸ | PDE8B | O95263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333012 | 0.97 | ALDH1A1 (0.45) | ALDH1A1CPT1ATSHRMEN1KMT2A | |
| SCHEMBL6326083 | 0.90 | MIF (0.41) | ALDH1A1CPT1ACPT2TSHRMEN1 | |
| SCHEMBL6328098 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL29176498 | 0.86 | CPT1A (0.47) | ALDH1A1CPT1ACPT2TSHRMEN1 | |
| SCHEMBL29176499 | 0.86 | CPT1A (0.47) | ALDH1A1CPT1ACPT2TSHRMEN1 | |
| SCHEMBL29176558 | 0.84 | CPT1A (0.46) | CPT1ACPT2MEN1KMT2ACPT1B | |
| SCHEMBL29176556 | 0.84 | CPT1A (0.46) | CPT1ACPT2MEN1KMT2ACPT1B | |
| SCHEMBL6326318 | 0.81 | MIF (0.40) | CPT1ACPT2TSHR | |
| SCHEMBL12649187 | 0.81 | ALDH1A1 (0.45) | ALDH1A1CPT1ACPT2TSHRMEN1 | |
| SCHEMBL6323599 | 0.81 | GPR119 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| CN-1568187-A | 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof | ICOS CORP (US) | 2005-01-19 | — | — | CN | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | ALDH1A1 338/4885CPT1A 762/4885CPT2 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.